TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

Migration, Crosslink

📖

TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-trap-ad-nct04784416

📖 Wiki Page

clinical2497 wordssynced 2026-04-02

TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

TRAP-AD (Transcranial Photobiomodulation for Alzheimer's Disease) is a Phase 2 randomized, triple-masked, sham-controlled clinical trial evaluating the efficacy and safety of transcranial near-infrared photobiomodulation (tPBM) in patients with amnestic mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The trial uses an 808 nm near-infrared laser device delivering 300 mW/cm² to the bilateral temporal and prefrontal regions over 24 treatments (3 sessions/week for 8 weeks), with cognitive outcomes assessed at 8 weeks and 3-month follow-up[@nct04784416][@iosifescu2022].

Overview

TRAP-AD represents one of the most rigorous clinical evaluations of photobiomodulation (PBM) for Alzheimer's disease to date. Unlike earlier pilot studies with small cohorts and open-label designs, TRAP-AD is a properly powered Phase 2 RCT with 196 participants, triple-masking (participant, care provider, investigator), and a validated primary cognitive endpoint[@iosifescu2022].

The trial is led by investigators at [NYU Langone Health](https://nyulangone.org), with additional sites at [Massachusetts General Hospital](https://www.massgeneral.org) and the [Nathan Kline Institute for Psychiatric Research](https://nki.rfmh.org). Funding comes from the [NIH](https://www.nih.gov), the [Alzheimer's Association](https://www.alz.org), and device manufacturer [LiteCure LLC](https://www.litecure.com).

...

TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

TRAP-AD (Transcranial Photobiomodulation for Alzheimer's Disease) is a Phase 2 randomized, triple-masked, sham-controlled clinical trial evaluating the efficacy and safety of transcranial near-infrared photobiomodulation (tPBM) in patients with amnestic mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The trial uses an 808 nm near-infrared laser device delivering 300 mW/cm² to the bilateral temporal and prefrontal regions over 24 treatments (3 sessions/week for 8 weeks), with cognitive outcomes assessed at 8 weeks and 3-month follow-up[@nct04784416][@iosifescu2022].

Overview

TRAP-AD represents one of the most rigorous clinical evaluations of photobiomodulation (PBM) for Alzheimer's disease to date. Unlike earlier pilot studies with small cohorts and open-label designs, TRAP-AD is a properly powered Phase 2 RCT with 196 participants, triple-masking (participant, care provider, investigator), and a validated primary cognitive endpoint[@iosifescu2022].

The trial is led by investigators at [NYU Langone Health](https://nyulangone.org), with additional sites at [Massachusetts General Hospital](https://www.massgeneral.org) and the [Nathan Kline Institute for Psychiatric Research](https://nki.rfmh.org). Funding comes from the [NIH](https://www.nih.gov), the [Alzheimer's Association](https://www.alz.org), and device manufacturer [LiteCure LLC](https://www.litecure.com).

The scientific rationale rests on photobiomodulation's ability to enhance [cytochrome c oxidase](/entities/cytochrome-c-oxidase) activity in neuronal mitochondria, increase [ATP](/entities/atp) production, reduce oxidative stress, and modulate neuroinflammation — all pathways that are impaired in Alzheimer's disease[@hamblin2016][@calvo2022].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | [NCT04784416](https://clinicaltrials.gov/study/NCT04784416) |
| Title | Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | NYU Langone Health |
| Collaborators | NIH, Alzheimer's Association, LiteCure LLC |
| Principal Investigators | Dan Iosifescu, MD (NYU Langone); Ricardo Osorio, MD (NYU Langone); Paolo Cassano, MD PhD (MGH) |
| Enrollment | 196 participants |
| Start Date | April 27, 2021 |
| Primary Completion | October 30, 2025 |
| Estimated Completion | January 31, 2026 |
| Locations | New York, NY; Boston, MA; Orangeburg, NY |
| Study Type | Interventional |
| Design | Randomized, triple-masked, parallel-group |

Study Design

Randomized Controlled Framework

TRAP-AD uses a rigorous three-arm parallel design:

| Arm | Intervention | Sessions |
|-----|-------------|----------|
| Active tPBM 2.0 | 808 nm NIR laser, 300 mW/cm², ~11 min/session, bilateral temporal + prefrontal | 24 treatments over 8 weeks |
| Sham tPBM 2.0 | Identical device, no active light output | 24 treatments over 8 weeks |
| Active tPBM 1.0 | (Lower-power protocol, dose-finding) | 24 treatments over 8 weeks |

Triple-masking ensures that:

Participants do not know their group assignment
Care providers do not know group assignment
Investigators assessing outcomes do not know group assignment

This design minimizes placebo effects, which are particularly important in studies of non-pharmacological interventions where patient expectations can strongly influence cognitive outcomes.

Dose Rationale

The trial investigates two dose levels of tPBM:

tPBM 2.0 (higher dose): 300 mW/cm², ~11 minutes per session — the primary focus of the Phase 2 evaluation[@iosifescu2022]
tPBM 1.0 (lower dose): dose-finding component to establish dose-response relationship

The 808 nm wavelength was chosen because near-infrared light in the 800-900 nm range penetrates skull and brain tissue most effectively, with peak absorption by [cytochrome c oxidase](/entities/cytochrome-c-oxidase) in the mitochondrial respiratory chain[@hamblin2016].

Intervention

Photobiomodulation Device and Parameters

The tPBM device delivers coherent near-infrared light (808 nm) transcranially:

| Parameter | Value |
|-----------|-------|
| Wavelength | 808 nm (near-infrared) |
| Power density | 300 mW/cm² |
| Treatment duration | ~11 minutes per session |
| Frequency | 3 sessions/week |
| Total sessions | 24 (over 8 weeks) |
| Total energy | ~15,840 J per site over course of treatment |
| Application sites | Bilateral temporal regions + prefrontal region |
| Device manufacturer | LiteCure LLC |

Treatment Protocol

Week 1-8: 24 treatments (3x per week)
├── Session 1: Bilateral temporal + prefrontal
├── Session 2: Bilateral temporal + prefrontal
└── Session 3: Bilateral temporal + prefrontal

Post-treatment: 3-month follow-up assessment

Each session applies light to multiple brain regions sequentially, targeting areas most affected by AD pathology:

Bilateral temporal cortex: Hippocampal and parahippocampal projections; memory consolidation
Prefrontal cortex: Executive function, working memory, attention

Mechanism of Action

Transcranial photobiomodulation operates through multiple biological pathways[@calvo2022][@salehpour2018]:

Mermaid diagram (expand to render)

Primary photoacceptor: Cytochrome c oxidase (Complex IV), the terminal enzyme in the mitochondrial electron transport chain. NIR light at 808 nm is absorbed by the CuA center of COX, enhancing oxygen consumption and ATP synthesis["@hamblin2016"].

Secondary mechanisms:

Nitric oxide release -> vasodilation -> increased cerebral blood flow
Reactive oxygen species (ROS) modulation -> reduced oxidative damage
Activation of transcription factors (Nrf2, PGC-1alpha) -> antioxidant response
Reduced pro-inflammatory cytokines (IL-1beta, TNF-alpha) -> neuroinflammation reduction
Increased [BDNF](/entities/bdnf) expression -> neurogenesis and synaptic plasticity["@tian2021"]

Neuroimaging Component

The trial includes the 18F-MK-6240 PET tracer for tau imaging, allowing researchers to:

Confirm participant amyloid/tau pathology status at baseline
Assess whether tPBM affects tau accumulation over the treatment period
Stratify analyses by baseline tau burden

Outcomes

Primary Outcome

| Measure | Scale | Timepoints |
|---------|-------|------------|
| RBANS Total Scale Index Score | Mean 100, SD 15 | Baseline, Week 8 (primary), Month 3 (follow-up) |

Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): A brief, standardized cognitive battery assessing immediate memory, visuospatial/constructional ability, language, attention, and delayed memory — well-validated in MCI and early AD populations[@iosifescu2022].

Secondary Outcomes

| Measure | Category | Timepoints |
|---------|----------|------------|
| ACE-III (Addenbrooke's Cognitive Examination III) | Global cognition | Baseline, Week 8, Month 3 |
| Letter Comparison Test | Processing speed | Baseline, Week 8, Month 3 |
| Pattern Comparison Test | Processing speed | Baseline, Week 8, Month 3 |
| Stroop Color and Word Test | Executive function / inhibition | Baseline, Week 8, Month 3 |
| Trail Making Test (A and B) | Executive function, set-shifting | Baseline, Week 8, Month 3 |
| FNAME-12 (Face-Name Associative Memory Exam) | Associative memory | Baseline, Week 8, Month 3 |
| Letter Number sequencing | Working memory | Baseline, Week 8, Month 3 |
| SAFTEE-SI (Side Effects Checklist) | Safety/tolerability | Weekly during treatment |

Outcome Hierarchy

The trial prioritizes cognitive outcomes across multiple domains:

Global Cognition (RBANS, ACE-III)
└── Processing Speed (Letter Comparison, Pattern Comparison)
└── Executive Function (Stroop, Trail Making)
└── Memory (FNAME-12, RBANS delayed memory)
└── Working Memory (Letter Number Sequencing)

This multi-domain assessment enables detection of both global and domain-specific treatment effects, which is important for a non-pharmacological intervention that may not produce uniform effects across all cognitive domains.

Eligibility Criteria

Inclusion Criteria

Age: 65-85 years

Diagnosis: Amnestic MCI or early Alzheimer's disease

Cognitive staging:

Clinical Dementia Rating (CDR) 0.5 or 1.0
Functional Assessment Staging Test (FAST) 1-4

4. Education: Minimum high school education (to ensure reliable neuropsychological testing)

Language: Fluent English

Stability: Stable medications for at least 30 days prior to enrollment

Exclusion Criteria

Other dementias: Diagnosis of vascular dementia, frontotemporal dementia, Lewy body dementia, or other neurodegenerative conditions

Cerebrovascular disease: Significant history of stroke, TIA, or large vessel disease

Psychiatric illness: Major depressive disorder, bipolar disorder, schizophrenia, active substance use disorder

Neurological conditions: Epilepsy, traumatic brain injury with loss of consciousness >30 min

Light-sensitive conditions: Conditions contraindicating NIR light exposure (e.g., porphyria, photophobia)

Devices: Cardiac pacemakers or other electronic implants

Medical conditions: Uncontrolled diabetes, active cancer, severe cardiac or pulmonary disease

Medications: High-dose benzodiazepines, anticholinergics, or other cognitive-affecting drugs

Rationale for Key Criteria

CDR 0.5-1.0: This range captures both MCI (CDR 0.5) and mild AD (CDR 1.0), ensuring the intervention is tested in the population most likely to benefit — those with established pathology but sufficient neural reserve for treatment effects.

Exclusion of other dementias: Ensures the study population has probable AD pathology, reducing heterogeneity that could obscure treatment effects. Confirmed via 18F-MK-6240 PET tau imaging.

Light-sensitive conditions: Although tPBM at 808 nm is considered safe, photosensitivity disorders are an absolute contraindication to any phototherapy.

Sites and Personnel

NYU Langone Health (Lead Site)

Dan Iosifescu, MD — Principal Investigator, Director of Mood and Anxiety Disorders Research Program
Ricardo Osorio, MD — Co-Principal Investigator, Center for Brain Health
Contact: NYU Langone Health, Department of Psychiatry, New York, NY

Massachusetts General Hospital

Paolo Cassano, MD, PhD — Co-Investigator, Director of Photobiomodulation Research Program
Depressive Disorders and Photobiomodulation Laboratory, Department of Psychiatry, MGH
Contact: Massachusetts General Hospital, Boston, MA

Nathan Kline Institute for Psychiatric Research

Site for additional enrollment and neuroimaging assessments
Orangeburg, NY (affiliated with Columbia University Department of Psychiatry)

Rationale for Multi-Site Design

The multi-site structure enables:

Recruitment of 196 participants within the study timeline
Geographic diversity (NYC and Boston metro areas)
Cross-validation of outcomes across sites
Larger sample for subgroup analyses by age, disease stage, and baseline tau burden

Safety Profile of tPBM

Photobiomodulation Safety

Transcranial photobiomodulation at 808 nm and 300 mW/cm² has an excellent safety profile established through decades of use in dermatology, wound healing, and neurological applications[@salehpour2018]:

| Side Effect | Frequency | Notes |
|-------------|-----------|-------|
| Mild warmth at site | Common, transient | Resolves within minutes post-session |
| Headache | Rare | Usually mild, self-resolving |
| Eye irritation | Rare | Protective eyewear used during all sessions |
| Skin erythema | Very rare | Self-resolving, no scarring |

Key Safety Distinctions from Other Light Therapies

Unlike bright visible light therapy (used for seasonal affective disorder), tPBM uses:

Near-infrared (invisible) light — no photophobic or photosensitizing effects
Coherent (laser) vs. incoherent (LED) — deeper tissue penetration
Higher fluence — targeted for mitochondrial rather than circadian effects

Contraindications

Photosensitivity disorders (porphyria, lupus, etc.)
Active cancer in treatment area
Metal implants in beam path (safety concern)
Seizure disorders (theoretical concern with thermal effects)

Prior Evidence for tPBM in Alzheimer's Disease

Preclinical Evidence

Animal models support tPBM's mechanism in AD[@tian2021][@bck2022]:

APP/PS1 mice: tPBM reduced amyloid-beta accumulation, improved mitochondrial function, and restored spatial memory
3xTg-AD mice: tPBM decreased tau hyperphosphorylation and neuroinflammation
In vitro: tPBM enhanced neuronal survival against oxidative stress and excitotoxicity

Human Pilot Studies

Several small open-label or single-blind studies preceded TRAP-AD[@berman2019][@bck2022]:

| Study | N | Design | Result |
|-------|---|--------|--------|
| Berman et al. (2019) | 13 MCI | Open-label, NIR helmet | Improved RBANS, ADAS-Cog |
| Saltmarche et al. (2017) | 8 moderate AD | Open-label, intranasal + transcranial | Improved ADAS-Cog, Neuropsychiatric Inventory |
| Bickerton et al. (2021) | 30 AD | RCT, LED helmet | Improved ACE-R, CANTAB memory |
| Blomer et al. (2020) | 11 mild AD | Open-label, transcranial | Improved cognitive composite, reduced neuroinflammation |

Limitation: All prior studies were small (N < 50), mostly unblinded, and used heterogeneous devices/protocols — insufficient for regulatory or clinical adoption.

TRAP-AD's Contribution

TRAP-AD is designed to overcome these limitations:

196 participants — adequately powered for primary endpoint
Triple-masked RCT — eliminates expectation bias
Standardized device (LiteCure) — reproducible parameters
Multi-site — generalizable results
Tau PET imaging — mechanistic biomarker validation

Connection to AD Mechanisms

TRAP-AD intersects with multiple Alzheimer's disease mechanisms:

Mermaid diagram (expand to render)

[Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-alzheimers) — Primary tPBM target
[Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers) — Downstream benefit
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis) — tPBM may reduce Abeta burden
[Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-alzheimers) — BDNF-mediated protection

Comparison with Other AD Interventions

| Intervention | Mechanism | Stage | Primary Route |
|--------------|-----------|-------|---------------|
| TRAP-AD tPBM | Mitochondrial enhancement | Phase 2 | Non-invasive transcranial |
| Lecanemab | Anti-amyloid antibody | Approved | IV infusion |
| Donanemab | Anti-amyloid antibody | Approved | IV infusion |
| Blarcamesine | Muscarinic agonist | Phase 3 | Oral |
| Buntanetap | α-synuclein translation inhibitor | Phase 3 | Oral |
| SPG302 | Microtubule stabilization | Phase 1 | Oral |

tPBM is unique among AD interventions in its non-pharmacological, non-invasive approach targeting cellular energy metabolism rather than a specific pathological protein.

Significance and Expected Impact

Scientific Significance

TRAP-AD, if positive, would represent a paradigm shift in AD treatment:

Non-pharmacological: No drug-drug interactions, excellent safety profile

Disease-modifying mechanism: Targets mitochondria rather than amyloid/tau directly

Synergistic potential: Could be combined with anti-amyloid antibodies or symptomatic treatments

Home-use potential: After dose optimization, patients could self-administer

Clinical Significance

A successful tPBM intervention would:

Fill the gap for patients with MCI/early AD who cannot receive anti-amyloid antibodies (due to ApoE4 homozygosity, ARIA risk, or availability)
Provide an adjunctive therapy that complements pharmacological approaches
Offer a tolerable treatment for patients with multiple comorbidities

Limitations

Treatment burden: 24 clinic visits over 8 weeks — significant for elderly patients with cognitive impairment
Device dependence: Requires specialized equipment, limiting home use during development
Unknown durability: Effects at 3 months post-treatment are unknown
Heterogeneity: AD patients with different underlying pathologies may respond variably

Cross-Links

[Photobiomodulation Therapy for Neurodegeneration](/therapeutics/photobiomodulation-therapy-neurodegeneration)
[Photobiomodulation for Parkinson's Disease](/therapeutics/photobiomodulation-parkinsons-disease)
[Non-Invasive Brain Stimulation](/treatments/non-invasive-brain-stimulation)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mci)
[Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-alzheimers)
[Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
[Cytochrome C Oxidase](/entities/cytochrome-c-oxidase)
[ATP](/entities/atp)
[BDNF](/entities/bdnf)

References

[NCT04784416 — TRAP-AD Transcranial Photobiomodulation for Alzheimer's Disease](https://clinicaltrials.gov/study/NCT04784416)[@nct04784416]

[Iosifescu D, et al., TRAP-AD protocol: randomized double-blind sham-controlled trial. BMJ Open. 2022](https://doi.org/10.1136/bmjopen-2021-059045)[@iosifescu2022]

[Hamblin MR, Photobiomodulation for Alzheimer's disease. J Alzheimers Dis. 2016](https://pubmed.ncbi.nlm.nih.gov/27232415/)[@hamblin2016]

[Johnstone DM, et al., Photobiomodulation for Parkinson's disease. J Parkinsons Dis. 2019](https://pubmed.ncbi.nlm.nih.gov/31306117/)[@johnstone2019]

[Huang YY, et al., Biphasic dose response in low level light therapy. Dose-Response. 2011](https://pubmed.ncbi.nlm.nih.gov/22107877/)[@huang2011]

[Salehpour F, et al., Transcranial photobiomodulation for brain disorders. Photomed Laser Surg. 2018](https://pubmed.ncbi.nlm.nih.gov/29529291/)[@salehpour2018]

[Calvo S, et al., Mechanisms of action of PBM in the brain: the role of mitochondrial dynamics. Front Neurol. 2022](https://doi.org/10.3389/fneur.2022.1030019)[@calvo2022]

[Boutou AK, et al., Near-infrared light in neurodegenerative diseases. Photobiomodulation Photomed Laser Surg. 2022](https://doi.org/10.1089/photob.2021.0134)[@bck2022]

[Tian S, et al., PBM reduces amyloid-beta accumulation and improves mitochondrial function in AD mouse model. J Alzheimers Dis. 2021](https://pubmed.ncbi.nlm.nih.gov/33903601/)[@tian2021]

[Berman MH, et al., Photobiomodulation with NIR light helmet in mild cognitive impairment. J Neurol Neurosci. 2019](https://www.imrpress.com/journal/JNV/10/1/10.36922/jnv.v10i1.1153)[@berman2019]

📖 View canonical wiki page →

Related Entities

clinical-trials-trap-ad-nct04784416

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-trap-ad-nct04784416
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b97c948606f3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-trap-ad-nct04784416'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

591

Outgoing

649

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

Overview

TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)

Overview

Trial Details

Study Design

Randomized Controlled Framework

Dose Rationale

Intervention

Photobiomodulation Device and Parameters

Treatment Protocol

Mechanism of Action

Neuroimaging Component

Outcomes

Primary Outcome

Secondary Outcomes

Outcome Hierarchy

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Rationale for Key Criteria

Sites and Personnel

NYU Langone Health (Lead Site)

Massachusetts General Hospital

Nathan Kline Institute for Psychiatric Research

Rationale for Multi-Site Design

Safety Profile of tPBM

Photobiomodulation Safety

Key Safety Distinctions from Other Light Therapies

Contraindications

Prior Evidence for tPBM in Alzheimer's Disease

Preclinical Evidence

Human Pilot Studies

TRAP-AD's Contribution

Connection to AD Mechanisms

Comparison with Other AD Interventions

Significance and Expected Impact

Scientific Significance

Clinical Significance

Limitations

Cross-Links

References

💬 Discussion